DUPIXENT was studied in 2 pivotal trials of adult patients with prurigo nodularis
PRIME and PRIME2 assessed the effect of DUPIXENT on itch improvement, as well as its effect
on PN nodules.1,2
3X
as many patients in PRIME had
significantly reduced itch at Week 24
(60% with DUPIXENT vs 18% with
placebo; P<0.001, primary endpoint)
PRIME2
37% of DUPIXENT patients achieved a meaningful response at Week 12 vs 22% with placebo; P=0.022 (primary endpoint). At Week 24, 58% of DUPIXENT patients achieved significant itch relief vs 20% with placebo; P<0.001 (secondary endpoint)
2.5X
as many patients in PRIME achieved
significant nodule clearance
(IGA PN-S 0 or 1) at Week 24 (48%
with DUPIXENT vs 18% with placebo;
P<0.001, secondary endpoint)
PRIME2
45% of DUPIXENT patients similarly achieved significant nodule clearance (IGA PN-S 0 or 1) at Week 24 vs 16% with placebo; P<0.001 (secondary endpoint)
Explore itch results and nodule
clearance data
Demonstrated safety profile1
- Most common adverse reactions in adult patients with prurigo nodularis (incidence ≥2%) are:
- Nasopharyngitis
- Conjunctivitis
- Herpes infection
- Dizziness
- Myalgia
- Diarrhea
- No patients treated with DUPIXENT (0%) discontinued treatment due to adverse events vs 3% with placebo
- Patients should discontinue DUPIXENT if a clinically significant hypersensitivity reaction occurs or until a parasitic (helminth) infection resolves in a patient who does not respond to anti-helminth treatment
IGA PN-S, Investigator’s Global Assessment PN-Stage; WI-NRS, Worst Itch numeric rating scale.
Dosage and administration
information you need to get started.